DGAP-Adhoc

Carl Zeiss Meditec AG successfully completes capital increase

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Capital Increase/Corporate Action Carl Zeiss Meditec AG successfully completes capital increase 22-March-2017 / 08:12 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   Carl Zeiss Meditec AG successfully completes capital increase     JENA, 22 March 2017

Carl Zeiss Meditec AG raises proceeds of around EUR 317 million from the capital increase.

Carl Zeiss Meditec AG (ISIN: DE0005313704), (the "Company") has successfully concluded the capital increase announced yesterday. The order book was closed early due to the strong demand.

A total of 8,130,960 new shares were placed at a price of EUR 38.94 per share. The gross proceeds to the Company from the capital increase amount to approximately EUR 317 million. The new shares shall be admitted to trading on the regulated market of the Frankfurt Stock Exchange, with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard). The first trading day of the new shares is scheduled for 27 March 2017.

Contact for investors and press

Sebastian Frericks

Director Investor Relations Carl Zeiss Meditec AG

Phone: [phone]

Email: [e-mail]

www.zeiss.de/presse

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Carl Zeiss Meditec AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to confirm them to future events or developments.